Sanofi has announced plans to acquire US-based vaccines biotechnology company, Protein Sciences Corporation.

The French healthcare company will pay up to $750m for the acquisition, which will add recombinant-based influenza vaccine to its portfolio.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

GE Healthcare has announced the acquisition of healthcare consulting firm Novia Strategies.

Novia Strategies will be incorporated into GE Healthcare Camden Group, complementing the division in areas such as care management transformation and non-labour cost reduction.

"GE Healthcare has announced the acquisition of healthcare consulting firm Novia Strategies."

The acquisition will also enable GE Healthcare to expand its healthcare consulting business in the US.

Both companies involved in the acquisition are based in the US.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Canadian pharmaceutical company Medicure plans to acquire an additional stake in Apicore Inc. and Apicore LLC (together 'Apicore') for $24.5m.

The acquisition is being made through Medicure’s wholly owned Mauritius subsidiary and will increase the company’s ownership in Apicore Inc. to 98%.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact